Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6040 Phase I in Advanced Solid Tumors
NCT06970795Phase 1Recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SYS6040 in solid tumor and small cell lung cancer (SCLC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events at 2 years and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
SYS6040
03
Conditions
solid tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06970795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970795.